TFA Therapeutics (RAJAF) Non-Current Assets (2020 - 2025)

TFA Therapeutics has reported Non-Current Assets for 6 years, with the latest figure at $3.7 million in Q4 2025.

• On a quarterly basis, Non-Current Assets fell 9.01% year-over-year to $3.7 million in Q4 2025; TTM through Dec 2025 was $12.5 million, a 19.78% increase from a year earlier, with the FY2025 full-year figure at $3.7 million, down 9.01% from the prior year.
• Non-Current Assets was $3.7 million for Q4 2025 at TFA Therapeutics, down from $4.0 million in the prior quarter.
• The five-year high for Non-Current Assets was $4.0 million in Q4 2024, with the low at $1.6 million in Q4 2022.
• Average Non-Current Assets over 5 years is $2.7 million, with a median of $2.6 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets slipped 24.81% in 2022, then surged 88.65% in 2023.
• Over 5 years, Non-Current Assets stood at $2.1 million in 2021, then dropped by 24.81% to $1.6 million in 2022, then soared by 88.65% to $3.0 million in 2023, then soared by 32.98% to $4.0 million in 2024, then decreased by 9.01% to $3.7 million in 2025.
• The last three Non-Current Assets figures came in at $3.7 million (Q4 2025), $4.0 million (Q4 2024), and $3.0 million (Q4 2023), per Business Quant data.